Daily FNArena News

You are hereby invited to participate in the July Investor Sentiment Survey. Your contribution is greatly appreciated, but you’ll have to do it now as the Survey closes at midnight.

A decision by the US National Comprehensive Cancer Network to recommend breast cancer patients be monitored for lymphoedema is considered a boost to Impedimed’s prospects.

Peter Switzer of the Switzer Super Report argues the case for an improving global economy and its impact on commodities and stock markets.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. One broker believes the market’s profit growth expectations for Orica are unrealistic the stock is vulnerable to a rebasing of forecasts.

The Chartist reports the technicals are lining up for CSL to gather momentum to the upside.

Sonic Healthcare is the second pathology provider to issue an earnings downgrade in a week, as funding cuts pressure the industry.

Lack of clear interest from either buyers or sellers ensured the uranium spot price remained unchanged yet again last week.

Michael Gable of Fairmont Equities suggests Greencross appears to be reversing to the upside.

Facilities management software provider Urbanise.com is well placed to leverage earnings growth from its cloud-based platform. Canaccord Genuity initiates coverage.

Private hospital operator Healthscope is expected to weather insurer rate reductions, given its margins are among the highest in the sector. Morgan Stanley initiates coverage.